Paragon Wealth Strategies’s Monopar Therapeutics MNPR Stock Holding History

Paragon Wealth Strategies’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12	Closed	-$137	–	158
2022 Q4	$137	Hold	12	–	–	﹤0.01%	243
2022 Q3	$0	Buy	+12	New	+$114	﹤0.01%	180
2021 Q3	–	Sell	-12	Closed	–	–	192
2021 Q2	$0	Buy	+12	New	+$344	﹤0.01%	293

Other funds holding MNPR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KPWS

Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return

RRCM

Rappaport Reiches Capital Management Skokie`, Illinois $400M AUM 7.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Paragon Wealth Strategies's MNPR Position: Q1 2023 in Review

Paragon Wealth Strategies sold out of Monopar Therapeutics (MNPR) in Q1 2023, closing a stake of 12 shares — an estimated $137 sold.

Paragon Wealth Strategies first reported a position in MNPR in Q2 2021 and held it in 3 quarters. The position peaked at $137 in Q4 2022. 11 funds tracked by Wall St. Rank hold MNPR as of Q1 2023.

Paragon Wealth Strategies reported no remaining Monopar Therapeutics position as of Q1 2023 after selling out during the quarter.
Paragon Wealth Strategies sold 12 Monopar Therapeutics shares in Q1 2023, an estimated $137.
Paragon Wealth Strategies first reported a position in Monopar Therapeutics in Q2 2021 and held it in 3 quarters.
Paragon Wealth Strategies's Monopar Therapeutics position peaked at $137 in Q4 2022.
11 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2023.

Based on Paragon Wealth Strategies's 13F filing for Q1 2023, filed 26 Apr 2023.